Halozyme Therapeutics Inc. (HALO)

Finanzdaten der Halozyme Therapeutics Inc.-Aktie (HALO)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-09-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	6.48% 230.04	216.03	221.04	162.14	208.98
Cost Of Revenue	4.61% 52.30	54.82	50.07	35.17	47.32
Gross Profit	10.25% 177.74	161.21	170.97	126.97	161.66
Operating Expenses	5.18% 76.71	72.93	76.51	73.17	78.36
Interest Income/Expense	15.87% 5.22	4.505	4.494	4.543	7.514
Benefits Costs and Expenses	12.77% 128.86	114.27	127.88	109.91	135.27
Costs And Expenses	0.98% 129.00	127.75	126.58	108.34	125.68
Operating Income/Loss	14.45% 101.03	88.28	94.46	53.80	83.29
Income/Loss From Continuing Operations Before Tax	0.57% 101.17	101.76	93.16	52.24	73.71
Income Tax Expense/Benefit	20.76% 15.79	19.92	18.40	12.62	12.07
Income/Loss From Continuing Operations After Tax	4.34% 85.39	81.84	74.75	39.62	61.63
Net Income/Loss	4.34% 85.39	81.84	74.75	39.62	61.63
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	100.73% -0.969	131.97	131.73	135.03	136.53
Diluted Average Shares	100.77% -1.036	134.08	133.54	137.90	139.39
Basic Earnings Per Share	4.84% 0.65	0.62	0.57	0.29	0.45
Diluted Earnings Per Share	6.56% 0.65	0.61	0.56	0.29	0.44
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-